Alzheimer's drugs: Does reducing amyloid work?

Article Medicine, General & Internal

Donanemab in Early Alzheimer's Disease

Mark A. Mintun et al.

Summary: In this study, donanemab showed improved composite scores for cognition and daily living activities compared to placebo in patients with early Alzheimer's disease at 76 weeks, although secondary outcomes varied. Longer and larger trials are needed to further explore the efficacy and safety of donanemab in Alzheimer's disease.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis

Sarah F. Ackley et al.

Summary: Pooled evidence from 14 randomized controlled trials targeting amyloid mechanism suggests that reducing amyloid levels does not substantially improve cognition.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Clinical Neurology

Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease

Jing Qian et al.

Summary: The study found that compared to the APOE epsilon 3/epsilon 3 reference genotype, the APOE epsilon 2 and epsilon 4 alleles have opposite effects on the rate of cognitive decline. These effects are clinically relevant and largely independent of the differential APOE allele effects on AD and comorbid pathologies, indicating that APOE genotype contributes to the heterogeneity in the rate of clinical progression in AD.

NEUROLOGY (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Progress with Treatments for Alzheimer's Disease

Allan I. Levey

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Clinical Neurology

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Chad J. Swanson et al.

Summary: BAN2401-G000-201 trial aimed to establish the effective dose and observe the treatment effect. While not meeting the primary endpoint at 12 months, results at 18 months demonstrated reduction in brain amyloid and improvement across multiple clinical and biomarker endpoints.

ALZHEIMERS RESEARCH & THERAPY (2021)

Add to Collection

Letter Clinical Neurology

Brain volume loss due to donanemab

Scott Ayton

EUROPEAN JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease

Jing Qian et al.

Summary: The study found that compared to the APOE epsilon 3/epsilon 3 reference genotype, the APOE epsilon 2 and epsilon 4 alleles have opposite effects on the rate of cognitive decline in Alzheimer's disease patients, which are clinically relevant and largely independent of the differential effects of APOE alleles on AD and comorbid pathologies.

NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology